MedTrace Logo

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

NCT03058406 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 256

Last updated 2020-04-06

No results posted yet for this study

Summary

The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Eribulin mesylate

Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2018-11-04
Completion
2018-11-04

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058406 on ClinicalTrials.gov